ClinicalTrials.gg
RecruitingNCT06138236PFESWTCPUpdated Dec 8, 2025

Plantar Fascitiis: Comparison of ESWT and Collagen Hydrolyzed Peptides

An Early Phase 1 interventional study of Collagen hydrolyzed peptides in Plantar Fascitis, sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients suffering from Plantar Fasciitis were randomized into three groups:

the first group underwent infiltration of Collagen Hydrolyzed Peptides, the second one underwent the ESWT treatment, the third one underwent a combination of the two treatments.

Read the detailed description

Patients suffering from Plantar Fasciitis were randomized into three groups:

the first group underwent infiltration of Collagen Hydrolyzed Peptides, the second one underwent the ESWT treatment, the third one underwent a combination of the two treatments.

Aim of the study was to consider any difference in the outcome of the three groups of patients. The NRS and the AFAS score were considered for the outcome measurement.

02

Conditions studied

  • Plantar Fascitis
03

In context

Lead sponsor

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari is the lead sponsor of 47 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Plantar fascitiis Aged between 18 and 80 years old

Exclusion criteria

Exclusion Criteria:

  • Previous surgery of the foot
  • to ESWT
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Infiltration

    1\. Infiltration of collagen hydrolyzed peptides

    Drug: Collagen hydrolyzed peptides

  • Experimental
    ESWT(Extracorporeal Shockwave Therapy)

    ESWT (Extracorporeal Shockwave Therapy)

    Drug: Collagen hydrolyzed peptides

  • Experimental
    Combination

    Combination of both treatments

    Drug: Collagen hydrolyzed peptides

Interventions

06

What researchers measure

Primary outcomes

  1. VAS (Visuoanalogic scale)

    Visuoanalogic Scale during walking. Range 0 (No pain) -10 (maximum pain)

    Time frame: Between recruitment and 30 days

  2. AFAS (American Foot and Ankle Score) is the American Foot and Ankle Scale

    It is a measurement of active ROM and deambulation of the patient. Range 0 (no function) -100 (perfect function)

    Time frame: Between Recruitment and 15 days

  3. AFAS is American Foot and Ankle Scale

    It is a measurement of active ROM and deambulation of the patient (Range 0-100)

    Time frame: Between Recruitment and 30 days

  4. AFAS is American Foot and Ankle Scale

    It is a measurement of active ROM and deambulation of the patient (Range 0-100)

    Time frame: Between Recruitment and 60 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lai TW, Ma HL, Lee MS, Chen PM, Ku MC. Ultrasonography and clinical outcome comparison of extracorporeal shock wave therapy and corticosteroid injections for chronic plantar fasciitis: A randomized controlled trial. J Musculoskelet Neuronal Interact. 2018 Mar 1;18(1):47-54. PubMed 29504578 ↗
  • Sun K, Zhou H, Jiang W. Extracorporeal shock wave therapy versus other therapeutic methods for chronic plantar fasciitis. Foot Ankle Surg. 2020 Jan;26(1):33-38. doi: 10.1016/j.fas.2018.11.002. Epub 2018 Nov 13. PubMed 30502222 ↗
  • Xu D, Jiang W, Huang D, Hu X, Wang Y, Li H, Zhou S, Gan K, Ma W. Comparison Between Extracorporeal Shock Wave Therapy and Local Corticosteroid Injection for Plantar Fasciitis. Foot Ankle Int. 2020 Feb;41(2):200-205. doi: 10.1177/1071100719891111. Epub 2019 Nov 19. PubMed 31744313 ↗
  • Melese H, Alamer A, Getie K, Nigussie F, Ayhualem S. Extracorporeal shock wave therapy on pain and foot functions in subjects with chronic plantar fasciitis: systematic review of randomized controlled trials. Disabil Rehabil. 2022 Sep;44(18):5007-5014. doi: 10.1080/09638288.2021.1928775. Epub 2021 May 26. PubMed 34038642 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2025, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Nov 18, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06138236
Lead sponsor
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Jul 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 8, 2025

Study contacts

Silvana DE GIORGI, PI
Contact
silvana.degiorgi@uniba.it
3389821930
Silvana DE GIORGI, PI
principal investigator · University of Bari
Angela Notarnicola, AP
study chair · University of Bari

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Collagen

Start the discussion